Navigation Links
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Date:8/19/2007

SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $3.1 million, compared with revenues of $7.3 million for the second quarter of 2006. The net loss for the second quarter of 2007 was $8.2 million, or $0.21 per share, compared with a net loss of $3.2 million, or $0.11 per share, for the second quarter of 2006. The increase in net loss reflected a proactive reduction of contract manufacturing activity and higher spending for advancement of the company's independent development programs.

Based on anticipated activities for the remainder of 2007, including acceleration of the company's pandemic influenza vaccine program, the company is revising its projection to a full-year net loss of between $32 million and $37 million and a net cash burn for the full year, excluding equity investments, of $27 million to $32 million. Vical had cash and investments of $82 million at June 30, 2007.

Pandemic Influenza IND Allowed

-- Vical has received notification of Investigational New Drug (IND)

allowance for its Phase 1 trial of the company's

Vaxfectin(TM)-formulated pandemic influenza DNA vaccine, and now

expects to initiate the trial earlier than originally planned during

the second half of 2007.

Other Advances in Product Development Programs

-- The company's licensee, AnGes MG, Inc. (AnGes), reported positive

results following an interim efficacy evaluation in its Japanese Phase

3 angiogenesis trial of its gene-based Hepatocyte Growth Factor (HGF)

product candidate in patients with advanced peripheral arterial disease

(PAD). Based on the recommendation of an Independent Data Monitoring

Committee, AnGes ended the trial early and is preparing an application

for Japanese marketing approval.

-- Vical announced
'/>"/>

SOURCE Vical

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... Switzerland (PRWEB) , ... September 01, 2015 , ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring ... presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, ...
(Date:9/1/2015)... Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... and makes the massage robots more effective and humanlike than ever before. With the ... chairs, the Ogawa Refresh and the Ogawa Active SuperTrac. , As in its ...
(Date:9/1/2015)... NV (PRWEB) , ... September 01, 2015 , ... ... or Self-Directed Care is, how to access caregivers and what to look for ... valuable and pertinent information. , Founded in 2006 in Canoga Park, CA by ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... dating men and pick-up artists about their experiences of female beauty, women’s emotions, ... concerns, including penis issues, as well as their relationships with other men, documenting ...
(Date:9/1/2015)... Chicago, IL (PRWEB) , ... September 01, 2015 ... ... Traumeel™ and Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) ... I.A. Injections of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... Cancer Research Insitiute, UK suggests that women on tamoxifen have ... They report on a large scale trial of tamoxifen to ... to 65 years, from the UK, Australia, New Zealand and ... the women were considered as being at increased risk of ...
... effective delivery of drugs for a number of conditions. According to ... with the use of nasal sprays to treat allergies such as ... of delivering a drug, because it gets into the bloodstream fast ... fact, act quicker than the corresponding pill. Nasal sprays are already ...
... can control a stressful situation makes it easier on ... is potentially damaging to health because it increases blood ... responses may accumulate to increase the risk of heart ... stress is moderated by many psychological factors, such as ...
... that reduces the level of copper in the blood ... animals. Wilson's disease is a rare disorder where patients ... bodies. Researchers at the University of Texas, through research ... as tetrathiomolybdate (TM) that could fight cancer by lowering ...
... could be used to treat heart and lung disease. ... experiment in healthy young men,// the results of which ... and lung disease. ,They report that the ... hypertension (caused by conditions such as heart valve disease, ...
... in the American Journal of Clinical Nutrition it was observed ... the build up of plaque in the arteries that can ... can protect against the formation of plaque in the arteries. ... diagnosed with heart disease or who had suffered a heart ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: